Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 14/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873826 | 0.80 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8873833 | 0.80 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8873840 | 0.80 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8874543 | 0.77 | BCHE (0.51) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8874546 | 0.77 | BCHE (0.51) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8874541 | 0.77 | BCHE (0.51) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL6035722 | 0.76 | BCHE (0.63) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL13888119 | 0.76 | BCHE (0.69) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8964028 | 0.75 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL8964021 | 0.75 | BCHE (0.55) | BCHEMEN1KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |